Cost-effectiveness of HMG coenzyme reductase inhibitors: Whom to treat?

European Heart Journal

Volumn 22, Issue 9, 2001, Pages 751-761

  Van Hout, B A ^a   Simoons, M L ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness; HMG coenzyme reductase inhibitors; Treatment guidelines

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE;

ANALYSIS OF VARIANCE; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES;

EID: 0034936507     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2308     Document Type: Article

References (27)

1. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study
2. Cholesterol and mortality: 30 years of follow-up from the Framingham Study
3. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
9. The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin
10. Cost-effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S)
11. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy
12. Cost effectiveness of pravastatin in secondary prevention of coronary artery disease
13. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
14. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population
15. Cost-effectiveness of cholesterol-lowering drugs: A review of the evidence
16. Cholesterol lowering and the use of healthcare resources: Results of the Scandinavian Simvastatin Survival Study
17. Economic evaluation in the field of cardiology: Theory and practice
18. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The REgression GRowth Evaluation Statin Study (REGRESS)
19. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
20. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
21. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): Reduction in atherosclerosis progression and clinical events
22. Total cholesterol and risk of mortality in the oldest old
23. Retardation and arrest of progression or regression of coronary artery disease: A review
24. Ten year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type II diabetic and nondiabetic subjects
25. Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients
26. The ARTS study
27. The health care costs of smoking